Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShare-based Compensation (IS)
Others
Ratios

BioLineRx (BLRX) Non Operating Income (2023 - 2025)

Historic Non Operating Income for BioLineRx (BLRX) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • BioLineRx's Non Operating Income rose 5304.23% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year decrease of 2304.04%. This contributed to the annual value of $18.4 million for FY2024, which is 27039.47% up from last year.
  • According to the latest figures from Q3 2025, BioLineRx's Non Operating Income is $1.2 million, which was up 5304.23% from -$1.9 million recorded in Q2 2025.
  • In the past 5 years, BioLineRx's Non Operating Income ranged from a high of $7.8 million in Q2 2024 and a low of -$7.7 million during Q2 2023
  • Moreover, its 3-year median value for Non Operating Income was $1.2 million (2025), whereas its average is $1.3 million.
  • As far as peak fluctuations go, BioLineRx's Non Operating Income skyrocketed by 25397.81% in 2024, and later plummeted by 12370.95% in 2025.
  • BioLineRx's Non Operating Income (Quarter) stood at $3.0 million in 2023, then skyrocketed by 81.15% to $5.4 million in 2024, then tumbled by 78.5% to $1.2 million in 2025.
  • Its Non Operating Income stands at $1.2 million for Q3 2025, versus -$1.9 million for Q2 2025 and $7.6 million for Q1 2025.